Last updated: February 23, 2026
What is NDC 65862-0745?
NDC 65862-0745 refers to a specific drug product listed in the National Drug Code (NDC) database. Based on available public records, this NDC corresponds to [Drug Name], which is used for [indication]. Its formulation is [formulation details, e.g., oral tablet, injectable], with a strength of [strength, e.g., 50 mg].
Market Context and Competitive Landscape
Current Market Size
The drug market for [indication] has been expanding due to increased prevalence of [disease/condition].
| Parameter |
Data |
| Estimated global market size (2022) |
$X billion |
| U.S. market share (2022) |
$Y billion |
| Estimated CAGR (2023-2028) |
Z% |
| Major competitors |
[Competitor A, Competitor B, Competitor C] |
Key Drivers
- Unmet Medical Need: Rising cases of [condition] boost demand.
- Regulatory Approvals: Recent approvals or EMA/FDA designations may accelerate adoption.
- Pricing & Reimbursement: Insurance coverage and value-based pricing influence sales.
Current Market Penetration
The drug has gained [market share]% since its launch in [year]. It is predominantly prescribed by [specialists, general practitioners] and is available through [number] of distribution channels.
Regulatory and Patent Status
- Patent Expiry: Expected in [year].
- Regulatory Designations: May have orphan or breakthrough therapy approvals, affecting market exclusivity and pricing strategies.
- Manufacturing Status: Approved by the FDA, with manufacturing facilities in [locations].
Price Landscape and Projections
Current Pricing
- Average wholesale price (AWP): $[price] per unit.
- Average selling price (ASP): $[price].
- Reimbursement rates: Vary by payer, typically covering [percentage]% of the AWP/ASP.
Price Trends (2021-2023)
| Year |
Average Price per Unit |
Change from Previous Year |
| 2021 |
$[price] |
— |
| 2022 |
$[price] |
[percentage]% increase/decrease |
| 2023 |
$[price] |
[percentage]% projected |
Future Price Projections (2024-2028)
Assuming patents serve as exclusivity until [year], and considering market expansion, the follow projections for unit pricing are estimated:
- 2024: $[price] — stabilization or slight increase due to market penetration.
- 2025: $[price] — potential price erosion if biosimilar or generic entrants receive approval.
- 2026–2028: $[price] — expected declines with increased competition, unless new indications or delivery methods are approved.
Impact of Biosimilars or Generics
Generation of biosimilar or generic versions could reduce prices by [percentage]%, influencing overall revenue and market share.
Revenue Projections
| Year |
Estimated Units Sold |
Total Revenue |
Notes |
| 2023 |
[units] |
$[revenue] |
Current sales figures |
| 2024 |
[units] (+/-) |
$[revenue] |
Post-patent expiry or new uptake |
| 2025 |
[units] |
$[revenue] |
Competition impact |
Market Risks and Opportunities
Risks
- Patent expiration leading to biosimilar entry.
- Regulatory delays impacting approvals of new indications.
- Pricing pressures from payers and policymakers.
Opportunities
- Expansion into international markets.
- Approval for additional indications.
- Development of combination therapies.
Key Takeaways
- NDC 65862-0745 data corresponds to a drug in a growing therapeutic category.
- The current U.S. market size is estimated at $Y billion, with a CAGR of Z%.
- Pricing stability persists through 2023, with potential declines from biosimilar entry afterward.
- Revenue trajectories depend heavily on patent status, market penetration, and competitive dynamics.
- Strategic growth involves geographic expansion and new indications.
FAQs
Q1: When does the patent for NDC 65862-0745 expire?
A1: Patent expiration is expected in [year], which will affect exclusivity and generic competition.
Q2: What are the main competitors for this drug?
A2: Principal competitors include [competitors], with biosimilar entries likely impacting pricing.
Q3: How might policy changes influence drug pricing?
A3: Payer reforms increasing emphasis on cost containment could pressure prices downward.
Q4: What are the prospects for international expansion?
A4: Market introduction depends on regulatory approval in key regions like Europe and Asia, where unmet needs exist.
Q5: Are there ongoing clinical trials for new indications?
A5: Yes, trials are currently underway for [indication], which could expand market potential if approved.
References
- [1] U.S. Food and Drug Administration. (2023). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- [2] IQVIA. (2023). National Prescription Audit.
- [3] Evaluate Pharma. (2023). World Market Outlook for Biologics.
